23andMe is one of Silicon Valley’s latest unicorns – now valued at over $1B with over $491M in venture capital investment. While they provide a valuable service to consumers, should we be wary of handing over this immensely personal data?
23andMe pairs its database of genotypes with user-reported phenotypes to uncover new targets for drug discovery
Science brings you far, a ton of data brings you farther.
DNA analytics and the future of personalized medicine